Soteria launches to develop switchable, bispecific T-cell engagers

By The Science Advisory Board staff writers

May 17, 2021 -- Soteria Biotherapeutics has closed $42 million in financing to launch as an immuno-oncology company focused on developing next-generation switchable, bispecific T-cell engagers to treat solid tumor cancers.

The company has developed T-Lite T-cell engagers that are selectively switched on through oral administration of a small-molecule activator to modulate potent T-cell activity by controlling the timing, duration, and level of bispecific complex formation. The switchable activity enables precise on/off control over the timing and magnitude of T-cell redirection and cytotoxic activity, according to the company.

The new funding will support the further advancement of the T-Lite technology platform and building of a pipeline of T-Lite candidates in validated cancer targets.

The series A financing was led by Roche Venture Fund and 5AM Ventures with participation from M Ventures, Novartis Venture Fund and Alexandria Venture Investments.

Takeda to acquire Maverick Therapeutics
Takeda Pharmaceutical has exercised its option to purchase T cell-targeted immunotherapy developer Maverick Therapeutics for up to $525 million in...
Amunix secures $117M to move lead candidate to clinical trials
Amunix Pharmaceuticals has raised $117 million in financing to fund the advancement of its lead T-cell engager candidate into the clinic.
Revitope, Janssen to develop tumor-targeting bispecific antibodies
Revitope Oncology has entered into a collaboration with Janssen Biotech for the evaluation of Revitope's proprietary T-cell engager technology platform...
Janux, Merck partner on T-cell engager immunotherapies
Janux Therapeutics has entered into a strategic collaboration and licensing agreement with Merck to discover, develop, and commercialize next-generation...

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter